
51 - 200 Mitarbeiter
🏥 Gesundheitswesen
🍽️ Lebensmittel & Getränke
🧬 Biotechnologie
🔥 Finanzierung im letzten Jahr
💰 €30.000.000 Post-IPO Secondary - DBV Technologies im 2025-10
Healthcare • Food & Beverage • Biotechnology
DBV Technologies ist ein weltweit tätiges, in der klinischen Entwicklungsphase befindliches biopharmazeutisches Unternehmen, das epikutane Immuntherapien zur Behandlung von Nahrungsmittelallergien und anderen immunvermittelten Erkrankungen entwickelt. Gegründet von Kinderärzten, treibt das Unternehmen seine proprietäre VIASKIN® Pflastertechnologie durch klinische Studien voran – einschließlich Phase 3-Studien für ein Erdnusspflaster (DBV712) und Programme der frühen Phase für Milchallergie (DBV135) – mit dem Ziel, das Immunsystem durch kontrollierte Hautexposition gegenüber Antigenen umzuprogrammieren.
🕒 vor 13 Tagen
🗣️🇺🇸🇬🇧 Englisch erforderlich
Verbessern Sie Ihre Chancen auf ein Vorstellungsgespräch, indem Sie Ihre Lebenslauf-Bewertung vor der Bewerbung überprüfen.

51 - 200 Mitarbeiter
🏥 Gesundheitswesen
🍽️ Lebensmittel & Getränke
🧬 Biotechnologie
🔥 Finanzierung im letzten Jahr
💰 €30.000.000 Post-IPO Secondary - DBV Technologies im 2025-10
Healthcare • Food & Beverage • Biotechnology
DBV Technologies ist ein weltweit tätiges, in der klinischen Entwicklungsphase befindliches biopharmazeutisches Unternehmen, das epikutane Immuntherapien zur Behandlung von Nahrungsmittelallergien und anderen immunvermittelten Erkrankungen entwickelt. Gegründet von Kinderärzten, treibt das Unternehmen seine proprietäre VIASKIN® Pflastertechnologie durch klinische Studien voran – einschließlich Phase 3-Studien für ein Erdnusspflaster (DBV712) und Programme der frühen Phase für Milchallergie (DBV135) – mit dem Ziel, das Immunsystem durch kontrollierte Hautexposition gegenüber Antigenen umzuprogrammieren.
• Act as a subject matter expert on the health outcomes and economic impact of the VIASKIN Peanut Patch and the broader peanut allergy treatment landscape. • Engage with national and regional payers, pharmacy benefit managers, integrated delivery networks, employers, and population health key opinion leaders to provide scientific, clinical, and economic information about VIASKIN Peanut. • Communicate the value proposition of epicutaneous immunotherapy, including efficacy, safety, patch wear-time, and real-world relevance, to support informed coverage and formulary decisions. • Conduct educational programs, scientific presentations, and value-evidence discussions to enhance understanding of product outcomes data among payer and population health audiences. • Establish and maintain strong relationships with key external stakeholders, including medical and pharmacy directors, payer decision-makers, professional societies, and patient advocacy organizations in the food allergy community. • Disseminate health outcomes data, real-world evidence, health economic models, and budget-impact analyses to support informed decision-making by payers and population health customers. • Collaborate with internal cross-functional teams—including Market Access, Medical Affairs, Value & Access, Commercial, and Field Reimbursement—to align evidence strategies and ensure consistent, accurate messaging ahead of and through launch. • Provide training to internal teams on outcomes data and value evidence, ensuring a consistent and accurate understanding across the organization. • Address unsolicited inquiries from payers and population health decision-makers regarding product information, clinical data, and outcomes research, in accordance with applicable regulations and company policy. • Support investigator-initiated studies, real-world evidence generation, and other research initiatives that contribute to the understanding of health outcomes in pediatric peanut allergy. • Contribute to the development of strategic plans for health outcomes research, value-evidence communication, and payer engagement in support of the VIASKIN Peanut launch. • Collaborate with internal stakeholders to integrate health outcomes strategies into broader product launch, access, and commercialization plans. • Ensure that all communication and interactions comply with regulatory requirements, legal guidance, and company policies.
• PharmD, M.D., or Ph.D. in a health sciences–related field required; Master’s in pharmacoepidemiology, epidemiology, or health economics preferred. • Minimum of eight (8) years working in the pharmaceutical, biotechnology, or healthcare industry, with a minimum of five (5) years in a HEOR or payer-facing scientific function supporting product launches with U.S. Market Access teams. • Experience spanning medical and scientific affairs, outcomes research, clinical practice, academic, or U.S. managed-markets settings. • Therapeutic experience in allergy/immunology, pediatrics, and/or rare disease preferred; familiarity with the food allergy treatment landscape is a strong advantage. • Strong understanding of health outcomes research, epidemiology, and health economics. • Demonstrated experience engaging national and regional payers, PBMs, IDNs, and other organized customers in a scientific or value-evidence capacity. • Strong background and deep understanding of health economics, outcomes research methodologies, and evidence-generation techniques. • Demonstrated expertise in economic modeling, budget-impact analysis, data analysis, and interpreting clinical and real-world data to generate meaningful insights. • Stay updated on the latest industry trends, healthcare policies, and regulations impacting health economics and outcomes research, including those specific to pediatric and food allergy markets. • Maintain a deep understanding of therapeutic areas of interest to the organization, including disease mechanisms, the treatment landscape, and relevant market dynamics. • Excellent communication and presentation skills. • Strong proficiency with relevant regulatory guidelines and requirements related to HEOR studies and payer scientific exchange. • Understanding of compliance and ethical considerations in conducting research and engaging with payer decision-makers. • Possess excellent written and verbal communication skills to effectively convey complex HEOR concepts to both technical and non-technical stakeholders. • Ability to engage and build strong relationships with external stakeholders, including thought leaders and academic experts in the field of HEOR.
Jetzt Bewerben🕒 vor 13 Tagen
HEOR Director managing strategic healthcare quality and evidence generation for Boehringer Ingelheim products. Overseeing cross-functional collaboration and leading the HEOR strategy for multiple therapeutic areas.
🇺🇸 Vereinigte Staaten – Remote
💵 $200.000 - $316.000 / Jahr
⏰ Vollzeit
🔴 Experte
👔 Direktor
🦅 H1B-Visum-Sponsor
🗣️🇺🇸🇬🇧 Englisch erforderlich
🕒 vor 13 Tagen
Director of HEOR responsible for leading healthcare quality strategies in obesity and liver disease. Collaborating across functions to support brand value propositions in the US market.
🇺🇸 Vereinigte Staaten – Remote
💵 $200.000 - $316.000 / Jahr
⏰ Vollzeit
🔴 Experte
👔 Direktor
🦅 H1B-Visum-Sponsor
🗣️🇺🇸🇬🇧 Englisch erforderlich
🕒 vor 13 Tagen
Director leading and empowering a high-performing project management team. Managing staff development and building cohesive team culture in a mental wellbeing organization.
🇺🇸 Vereinigte Staaten – Remote
💵 $140.000 - $160.000 / Jahr
⏰ Vollzeit
🔴 Experte
👔 Direktor
🦅 H1B-Visum-Sponsor
🗣️🇺🇸🇬🇧 Englisch erforderlich
🕒 vor 13 Tagen
🇺🇸 Vereinigte Staaten – Remote
💵 $140.000 - $150.000 / Jahr
⏰ Vollzeit
🔴 Experte
👔 Direktor
🦅 H1B-Visum-Sponsor
🗣️🇺🇸🇬🇧 Englisch erforderlich
🕒 vor 13 Tagen
Director of Client Sales and Insights at Circana analyzing consumer data to enhance client relationships. Pursuing opportunities to leverage data solutions for informed decision-making and strategic growth.
🗣️🇺🇸🇬🇧 Englisch erforderlich